. Author manuscript; available in PMC: 2013 Apr 1.

Published in final edited form as: Arthritis Rheum. 2012 Feb 10;64(4):1263–1271. doi: 10.1002/art.34348

Table 2.

Crude and standardized rates of all malignancy and hematologic malignancy for the study cohorts. All rates are standardized to the age, sex, and race distribution of the “all children with JIA” cohort.

Cohort	Person-Years of Follow-Up	All Malignancy		Hematologic Malignancy
Cohort	Person-Years of Follow-Up	Crude Rate per 100K person-years (95% CI)	Standardized Rate	Crude Rate per 100K person-years (95% CI)	Standardized Rate
All children with JIA	12,614	79.3 (42.7–147.3)	79.3	23.8 (7.7–73.7)	23.8
JIA unexposed	5,671	105.8 (47.5–235.5)	106.5	17.6 (2.5–125.1)	21.1
JIA MTX without TNF inhibitor	3,894	77.0 (24.8–238.8)	75.9	51.3 (12.8–205.2)	46.2
JIA any TNF inhibitor	2,922	34.2 (4.8–242.9)	37.0	0 (0–126.3)	(zero)
Asthma	675,794	28.6 (24.8–32.9)	27.1	10.5 (8.3–13.3)	10.4
ADHD	391,984	17.4 (13.4–22.0)	23.7	7.4 (5.1–10.6)	9.3
SEER external control	---	---	15.0	---	6.1

JIA = juvenile idiopathic arthritis; ADHD = attention-deficit hyperactivity disorder; MTX = methotrexate or leflunomide; TNF inhibitor = etanercept, infliximab, or adalimumab; SEER = Surveillance Epidemiology and End Results